Megan manages 28bio operations with an emphasis on commercial activities and the integration of both quality management and HSSE (health, safety, security, and environmental) management. She earned her master’s degree in Biomedical Engineering from Tulane University and comes to us with a wide range of organizational experience from various industries. She is committed to ensuring 28bio delivers robust data to clients with quality, integrity, and reliability.

Jeff manages accounting and administration at 28bio. He comes to us from the non-profit arena where he spent many years working in project, grant, and financial management on a host of local and national efforts. Most recently he provided financial and grants management oversight for a local non-profit’s 5-year, $4 million contract under the Gulf Region Health Outreach Program, part of a four-state project to expand health care access along the Gulf Coast.

Thomas Hartung, MD PhD, is 28bio’s Consulting VP of Scientific Affairs and the inventor of the Mini-Brain platform. Thomas believed in 28bio's vision to change the paradigm for neurological drug development and chose 28bio to commercialize his groundbreaking technology. He is also the Doerenkamp-Zbinden-Chair for Evidence-based Toxicology at Johns Hopkins Bloomberg School of Public Health and the Whiting School of Engineering, Baltimore, in Environmental Health and Engineering. He is also the Director of Centers for Alternatives to Animal Testing of both Hopkins and the University of Konstanz, Germany. CAAT hosts the secretariat of the Evidence-based Toxicology Collaboration, the Good Read-Across Practice Collaboration, the Good Cell Culture Practice Collaboration, the Green Toxicology Collaboration and the Industry Refinement Working Group. He is the former Head of the European Commission’s Center for the Validation of Alternative Methods (ECVAM), Ispra, Italy, and has authored more than 550 scientific publications.